POLBF (Poolbeg Pharma) Interest Coverage: No Debt (1) (As of Dec. 2025) — 100% Below Median


What is Poolbeg Pharma Interest Coverage?

Poolbeg Pharma POLBF -20.36% Interest Coverage is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, Poolbeg Pharma ranks better than 99.2% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Poolbeg Pharma's Operating Income for the six months ended in Dec. 2025 was $-4.88 Mil. Poolbeg Pharma's Interest Expense for the six months ended in Dec. 2025 was $0.00 Mil. Poolbeg Pharma has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Poolbeg Pharma PLC has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Poolbeg Pharma's Interest Coverage or its related term are showing as below:

POLBF' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt

POLBF's Interest Coverage is ranked better than
99.2% of 377 companies
in the Biotechnology industry
Industry Median: 106.07 vs POLBF: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Poolbeg Pharma  (OTCPK:POLBF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Poolbeg Pharma Interest Coverage Related Terms

Poolbeg Pharma Interest Coverage Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Poolbeg Pharma Interest Coverage Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
No Debt No Debt No Debt No Debt No Debt

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only No Debt No Debt No Debt No Debt No Debt

POLBF vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Poolbeg Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Interest Coverage falls into.


Poolbeg Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Poolbeg Pharma's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Poolbeg Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-8.03 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Poolbeg Pharma had no debt (1).

Poolbeg Pharma's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Poolbeg Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-4.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Poolbeg Pharma had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Poolbeg Pharma (POLBF) has a Interest Coverage of No Debt (1) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Poolbeg Pharma and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Poolbeg Pharma's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Poolbeg Pharma ranks #3 out of 377 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Poolbeg Pharma's Interest Coverage too high?
Poolbeg Pharma's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Poolbeg Pharma ranks #3 out of 377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Poolbeg Pharma's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #3 out of 377 companies for Interest Coverage. This places Poolbeg Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 106.07. Historically, Poolbeg Pharma's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Interest Coverage is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.